X0202 SCHEDULE 13G 0001595855 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 08/05/2026 0001444192 Grace Therapeutics, Inc. 00439U104 103 CARNEGIE CENTER SUITE 300 PRINCETON, NJ 08540 Rule 13d-1(c) Opaleye Management Inc. MA 0.00 2748392.00 0.00 2748392.00 2748392.00 N 13.07 IA CO Opaleye, L.P. DE 0.00 2748392.00 0.00 2748392.00 2748392.00 N 13.07 PN Based on 21,035,930 shares of Common Stock outstanding as of August 5, 2026, consisting of (i) 16,274,026 shares of Common Stock outstanding as of July 28, 2026, as reported by Grace Therapeutics, Inc. in its 2026 proxy statement, and (ii) 4,761,904 shares of Common Stock issued by Grace Therapeutics, Inc. in a private placement on August 4, 2026, in which Opaleye, L.P. participated. James Silverman X1 0.00 2748392.00 0.00 2748392.00 2748392.00 N 13.07 IN Grace Therapeutics, Inc. 103 CARNEGIE CENTER SUITE 300 PRINCETON, NEW JERSEY, 08540 This statement is filed by (i) Opaleye Management Inc. (the "Adviser"), (ii) Opaleye, L.P. (the "Fund"), and (iii) James Silverman (collectively, the "Reporting Persons"). The Fund directly holds 2,748,392 shares of Common Stock, par value $0.0001 per share (the "Common Stock"), of Grace Therapeutics, Inc. (the "Issuer"). The Adviser, as investment adviser to the Fund, and Mr. Silverman, as the controlling person of the Adviser, may be deemed to beneficially own the 2,748,392 shares of Common Stock held directly by the Fund. The filing of this statement shall not be construed as an admission that any Reporting Person is the beneficial owner of any securities covered by this statement for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or otherwise. One Boston Place, 26th Floor, Boston, MA 02108 Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Delaware James Silverman - United States Y 2,748,392.00 13.07 % 0 2,748,392.00 0 2,748,392.00 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 99.1 Joint Filing Agreement by and among the reporting persons Opaleye Management Inc. /s/ James Silverman 08/07/2026 Opaleye, L.P. /s/ James Silverman 08/07/2026 James Silverman /s/ James Silverman 08/07/2026